Megan Deegan

Vice President of Partnerships at Greenphire        


As Greenphire's Vice President of Partnerships, Megan is responsible for leading the global strategy for CROs and strategic partnerships. Prior to joining Greenphire, she spent more than a decade at Medidata in various roles helping to build high performing teams and driving scale across the organization while supporting sponsors, academic institutions, government agencies, and hospitals.

Megan graduated from Rutgers University with a Bachelor's degree in Communication.

Contributing Author   in
Contract Research  

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Articles from Megan

What CROs Cite as Their Top Clinical Trial Challenges and How They Plan to Overcome Them in 2025

   349
What CROs Cite as Their Top Clinical Trial Challenges and How They Plan to Overcome Them in 2025

In a rapidly evolving clinical research landscape, there is a greater need now more than ever for pharma and biotech companies to outsource trial management activities to contract research organizations (CROs), which are taking on an increasingly strategic role.

CROs have become much more prominent as key partners throughout every stage of drug discovery, supporting patient recruitment, trial execution, regulatory compliance and more to ensure efficacy, efficiency and safety. In fact, according to a recent report, “the global contract research organization market size was valued at USD 52.19 billion in 2023 and is anticipated to reach around USD 104.60 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.”